Joseph D. Khoury, MD, FCAP, Professor and Executive Director of MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center in Houston, discusses TP53-mutant AML. TP53 has been shown to regulate hematopoietic functions under both physiologic and pathologic conditions, and TP53 mutations can confer adverse prognoses in AML. It is important to work with the hematology-oncology team to establish protocols for detecting TP53 AML at baseline to have tools in place for rapid diagnostic assessment and to assess treatment options in consultation with treating clinicians based on the results.